Glaxosmithkline Pharmaceuticals Ltd vs Venus Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2383 as of 18 May 12:01 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Venus Remedies Ltd changed from 5.5 on March 2021 to 8.8 on March 2025 . This represents a CAGR of 9.86% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Venus Remedies Ltd changed from ₹ 338.91 crore on March 2021 to ₹ 400.47 crore on March 2025 . This represents a CAGR of 3.39% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 1031 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -5.51% The revenue of Venus Remedies Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 182.78 crore. This represent the decline of -100% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 386.88 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -8.2% The ebitda of Venus Remedies Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 40.04 crore. This represent the decline of -100% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 277.86 crore over 8 quarters. This represents a CAGR of 23.45% The net profit of Venus Remedies Ltd changed from ₹ 1.22 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Venus Remedies Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Venus Remedies Ltd

Incorporated in 1989 Venus Remedies Limited, formerly known as Venus Glucose Pvt Ltd, was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited.
The Company was promoted and managed by Chaudhary & Family.
The Company is one of the handful player in pharmaceutical sector to launch injectables globally.
It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). At present, Venus focuses on specialized therapeutic areas including anti-infectives (antibiotics), oncology, neurology, pain management, and skin and wound care.
In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Venus Remedies Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Venus Remedies Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 41,330 Cr while Market cap of Venus Remedies Ltd is 1,220 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Venus Remedies Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Venus Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Venus Remedies Ltd?

As of May 18, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2439.75. On the other hand, Venus Remedies Ltd stock price is INR ₹913.05.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Venus Remedies Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Venus Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.